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Hepatitis B and C viruses (HBV and HCV) cause chronic hepatitis and hepatocellular carcinoma (HCC) by
poorly understood mechanisms. We show that cytokines lymphotoxin (LT) a and b and their receptor
(LTbR) are upregulated in HBV- or HCV-induced hepatitis and HCC. Liver-specific LTab expression in mice
induces liver inflammation and HCC, causally linking hepatic LT overexpression to hepatitis and HCC. Devel-
opment of HCC, composed in part of A6+ oval cells, depends on lymphocytes and IKappa B kinase
b expressed by hepatocytes but is independent of TNFR1. In vivo LTbR stimulation implicates hepatocytes
as themajor LT-responsive liver cells, and LTbR inhibition in LTab-transgenicmicewith hepatitis suppresses
HCC formation. Thus, sustained LT signaling represents a pathway involved in hepatitis-induced HCC.INTRODUCTION
A causal relationship between chronic hepatitis, hepatocellular
damage, fibrosis, and carcinogenesis is well established(El-Serag and Rudolph, 2007). Various etiologies, including
chronic alcohol consumption, chronic drug abuse, autoimmune
disorders, toxins (e.g., aflatoxin B), or infections with hepato-
tropic viruses (e.g., HBV, HCV), can lead to chronic hepatitis,SIGNIFICANCE
Pharmacological inhibition of LTbR signaling reduces pathogen- and concavalin A-induced liver injury, whereas LTbR
signaling on hepatocytes appears to be beneficial during liver regeneration. We demonstrate that sustained hepatic LT
expression in mice can be injurious, causing chronic hepatitis and HCC. Enhanced hepatic LTbR signaling might be of
potential clinical relevance because LTbR and its ligands are drastically increased in human HBV- and HCV-induced hepa-
titis and HCC, compared with normal livers or nonviral, benign liver diseases. Thus, hepatic LT signaling might be advanta-
geous if transiently active during liver regeneration, but detrimental if chronically triggered. We propose that suppression of
hepatic LTbR signaling might be beneficial in liver diseases with chronic LTa, LTb, or LIGHT overexpression.Cancer Cell 16, 295–308, October 6, 2009 ª2009 Elsevier Inc. 295
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Sustained Hepatic LT Signaling Causes HCCliver fibrosis, and cirrhosis. HBV and HCV infections are by far the
most common cause of chronic hepatitis in humans (Malhi et al.,
2006). Chronic HBV and HCV infections are frequently associ-
ated with HCC, the most prevalent primary human liver cancer
(El-Serag and Rudolph, 2007), and except for HBV infections,
liver cirrhosis precedes HCC in most cases. The exact mecha-
nisms driving hepatitis-induced liver cancer remain elusive.
Among others, aberrant expression of cytotoxic cytokines is
thought to be critically involved (Greten and Karin, 2004; Lee
et al., 2005; Lowes et al., 2003; Vainer et al., 2008).
The proinflammatory and homeostatic cytokines LTa and LTb
are members of the tumor necrosis factor (TNF) superfamily.
Under physiological conditions, LTs are expressed by activated
T-, B-, NK-, and lymphoid tissue inducer cells (Fu et al., 1998;
Ware, 2005) and are crucial for organogenesis and maintenance
of lymphoid tissues (Rennert et al., 1996; Tumanov et al., 2003).
Although LTb contains a transmembrane domain, LTa is soluble.
Consequently, LT can exist as membrane-bound heterotrimers
(LTa1b2 or LTa2b1) interacting with LTbR or as soluble secreted
homotrimers (LTa3) triggering TNF receptor (TNFR) 1 and
TNFR2 and the herpesvirus entry mediator receptor (HVEM)
(Browning et al., 1997; Ware, 2005). LTbR and TNFR1 signaling
can be activated by the HCV-core protein (Chen et al., 1997;
Zhu et al., 1998) involving the canonical or noncanonical
NF-kB signaling pathways (Ware, 2005; You et al., 1999).
Furthermore, HBV or HCV infections lead to increased hepatic
LT expression in vivo and in vitro (Lee et al., 2005; Lowes
et al., 2003), and HCV replication has been demonstrated to
depend on components of the LTbR signaling pathway in vitro
(Ng et al., 2007).
LTs can directly act on hepatocytes, which physiologically
express high levels of LTbR but little LT (Browning and French,
2002). T cell-derived LT and LIGHT (LT-like, exhibits inducible
expression, competes with HSV glycoprotein D for HVEM,
expressed by T-lymphocytes) signaling to hepatocytes controls
lipoprotein homeostasis (Lo et al., 2007). In addition, LT signaling
is important for liver regeneration through T cell-derived LT
expression (Tumanov et al., 2008) and regulates hepatic stellate
cell function and wound healing (Ruddell et al., 2008). Thus,
hepatic LTbR signaling controls liver homeostasis in both health
and disease.
Promotion of HCC formation by chronic inflammatory stimuli
has been recapitulated in various animal models. Ablation of
the multidrug resistance gene 2 (mdr2) induces cholestatic hepa-
titis and liver cancer (Pikarsky et al., 2004), and administration of
the chemical carcinogen diethylnitrosamine (DEN) causes acute
liver injury and HCC (Maeda et al., 2005). Liver-specific expres-
sion of the hepatitis B surface antigen (HBsAg) in mice demon-
strates that chronic immune-mediated liver cell injury is critical
for HCC formation (Nakamoto et al., 1998).
Triggering TNFR1 or LTbR induces the classical and alterna-
tive NF-kB signaling pathways, which are linked to inflamma-
tion-induced carcinogenesis (Greten and Karin, 2004). However,
the precise role of these pathways in HCC pathogenesis is
controversial (Vainer et al., 2008). Mice lacking IKappa B kinase
b (IKKb) specifically in hepatocytes (IkkbDhep) exhibit a marked
increase in DEN-induced HCC formation, suggesting a protec-
tive function of IKKb in HCC development (Maeda et al., 2005).
In contrast, NF-kB signaling promotes HCC development in296 Cancer Cell 16, 295–308, October 6, 2009 ª2009 Elsevier Inc.mdr2/ mice, and anti-TNFa treatment is protective (Pikarsky
et al., 2004). Interestingly, mice with a hepatocyte-specific dele-
tion of IKKg (also called NEMO) develop steatohepatitis and
HCC (Luedde et al., 2007). Consequently, the role of NF-kB
signaling in hepatocarcinogenesis might depend on the mouse
model and the type or degree of liver inflammation and injury
(Vainer et al., 2008). Here, we investigated a possible causal rela-
tionship between sustained hepatic LTbR-signaling, chronic
hepatitis, and HCC development.
RESULTS
Upregulation of LTa, LTb, and LTbR in HBV-
or HCV-Infected Human Livers and in HCC
The specific role of LT signaling in the pathogenesis of virus-
induced hepatitis and HCC formation is not completely defined.
We analyzed transcriptional levels of LTa, LTb, LIGHT, TNFa,
LTbR, and TNFR1 in human HBV- or HCV-induced chronic hepa-
titis and HCC or in nonviral HCC, compared with healthy liver
specimens (Figure 1; Figure S1 available with this article online).
LTa, LTb, and LTbR mRNA expression was increased, on
average, 27- to 210-fold in HBV- or HCV-induced hepatitis
and HCC (p < 0.001); LIGHT transcripts were less, but still signif-
icantly, elevated (on average, 23- to 25-fold; p < 0.001). Like-
wise, TNFR1 mRNA expression was significantly increased in
HBV- or HCV-induced hepatitis and HCC (on average, 27- to
29-fold; p < 0.0001). In contrast, TNFa was only slightly upregu-
lated in HBV-induced hepatitis (p = 0.04) but not in HCV-induced
hepatitis (p = 0.3) and HCC (p = 0.4).
In most cases, HCV genotype, degree of inflammation
(Knodell score), fibrosis (Metavir score), and liver enzyme levels
(ALT; AST) were assessed (Tables S1–S5). Levels of LTa, LTb,
and LTbR mRNA did not correlate with the degree of liver inflam-
mation (p = 0.5), fibrosis (p = 0.5), patient age (p = 0.5), sex
(p = 0.5), HCV genotype, or type of virus infection (HBV, HCV,
HBV/HCV coinfection in the case of some HCC; p = 0.5) (Fig-
ure S1; data not shown).
To determine whether upregulation of LT ligands and recep-
tors was specific for HBV- or HCV-induced liver diseases, we
examined transcript levels in nonviral liver diseases. These
included liver disorders with hepatitis (alcoholic steatohepatitis
[ASH], cholestasis [CH], primary biliary cirrhosis/autoimmune
cholangitis [PBC], and end-stage liver cirrhosis due to alcoholic
liver disease [CIR]) and liver diseases without inflammation (stea-
tosis [ST] and focal nodular hyperplasia [FNH]). Additionally,
other liver diseases (OLD), such as hemochromatosis/siderosis,
Wilson’s disease, focal liver fibrosis, a1-antitrypsin deficiency,
and nonviral HCC (NVH), were investigated.
Levels of LTa, LTb, and LTbRmRNA were significantly lower in
all nonviral liver diseases analyzed except NVH, compared with
virus-induced chronic hepatitis and HCC (LTa, p < 0.0001; LTb,
p = 0.05; LTbR, p < 0.0001; Figure 1; Figure S1). This was true
whether or not nonviral liver diseases were associated with
inflammation. LIGHT and TNFR1 mRNA expression in nonviral
liver diseases including NVH was similar to HBV- or HCV-
induced chronic hepatitis and HCC. In contrast, TNFa mRNA
expression was significantly higher in nonviral liver diseases
with inflammation and NVH, compared with healthy livers (p <
0.0001) or HBV- or HCV-induced hepatitis and HCC (p < 0.0001).
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Sustained Hepatic LT Signaling Causes HCCFigure 1. mRNA Expression of Some TNF-Superfamily and TNF-Receptor-Superfamily Members in Viral (HBV- and HCV-Induced) and
Nonviral Liver Diseases
Analysis of hepatic LTa, LTb, LTbR, LIGHT, TNFR1, and TNFa transcription by real-time PCR. Healthy individuals (Ctrl; n = 15), patients chronically infected with
HBV (n = 19) or HCV (n = 49), affected by HCC (n = 30), or suffering from various non-virus-related liver disorders were investigated. Non-virus-related liver
diseases with hepatitis include alcoholic steatohepatitis (ASH; n = 13), cholestasis (CH; n = 3), primary biliary cirrhosis/autoimmune cholangitis (PBC; n = 5),
end-stage liver cirrhosis due to alcoholic liver disease (CIR; n = 8), a1-antitrypsin deficiency (a1AT; n = 1), and focal liver fibrosis (FLF; n = 2). Non-virus-related
liver diseases without hepatitis include steatosis (ST; n = 5), hemochromatosis/siderosis (HE/SID; n = 3), and Wilson’s disease (WD; n = 1). Focal nodular hyper-
plasia (FNH; n = 8) was investigated as a benign primary liver tumor. Diseases such as a1AT (black circles), FLF (black triangles), HE/SID (black diamonds), and
WD (white diamonds) are listed under ‘‘other liver diseases’’ (OLD). Horizontal bars represent the average mRNA expression level. The y axis describes the DDCT
values on a log scale. Asterisks indicate statistical significance: *p% 0.05; **p < 0.001; ***p < 0.0001.2Increased Chemokine Expression in HBV-
or HCV-Induced Hepatitis and HCC
To confirm that proinflammatory signaling cascades are acti-
vated during HBV- or HCV-induced hepatitis and HCC forma-
tion, chemokine mRNA levels were measured (Figure S1).
CCL2, CCL3, CCL5, and CXCL10 mRNA expression was signif-
icantly higher in human HBV-induced (p < 0.0001) or HCV-
induced (p < 0.0001) hepatitis and HCC (p < 0.0001) than in
healthy controls. CXCL1 mRNA expression was significantly
increased in HBV-induced hepatitis (p < 0.0001) and HCC
(p = 0.02), but not in HCV-induced hepatitis (p = 0.07).
Upregulation of LTa, LTb, and LIGHT in Human
Hepatoyctes upon HCV Infection In Vitro
We next investigated whether LTa, LTb, LIGHT, and LTbR tran-
scripts can be upregulated in hepatocytes as a consequence
of viral infection. The human hepatocyte cell line Huh-7.5 (Blight
et al., 2002) was challenged with infectious HCVcc (Pietschmann
et al., 2006), and the expression of cytokines and chemokines
was measured (Figure S2A). At 48–72 hr after infection,
transcripts of LTa (p = 0.05), LTb (p = 0.05), LIGHT (p = 0.05),LTbR (p = 0.05), and chemokines (CCL2, CCL3, CXCL1, and
CXCL10) were increased (2- to 32-fold) in HCVcc-infected,
compared with noninfected Huh-7.5 cells.
Identification of Liver Cells Expressing LTbR
and Its Ligands in HBV or HCV Infections
To identify the cellular source of LTa, LTb, LTbR, and LIGHT
expression in human HCV-infected livers, cells were collected
from HCV-induced hepatitis and HCC (Figure 2A; Figure S2B).
Liver cells were sorted according to their CD45 surface expres-
sion, resulting in CD45-enriched (T and B cells; monocytes,
macrophages, and Kupffer cells; and dendritic and NK cells) or
CD45-depleted (hepatocytes, oval cells, and bile duct epithelial
and endothelial cells) fractions. Purity of these fractions was as-
sessed by real-time PCR for lymphocyte (CD3, CD20, and CD45)
or hepatocyte (cytokeratin 18) markers. CD45-depleted fractions
displayed only a minor contamination with CD45 mRNA (1%–
10%), and CD45-enriched fractions showed only a minor
amount of cytokeratin 18 mRNA transcripts (2%–20%;
Figure S2C; data not shown). Unsorted liver cells of healthy indi-
viduals were included as controls. Because of ethicalCancer Cell 16, 295–308, October 6, 2009 ª2009 Elsevier Inc. 297
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Sustained Hepatic LT Signaling Causes HCCconsideration, not enough human healthy liver tissue was avail-
able in order to perform cell sorting.
Within HCV-induced HCC, CD45-enriched and -depleted liver
cells expressed similar LTa or LTb mRNA levels (LTa, p = 0.8;
LTb, p = 0.1) that were significantly higher than in controls
(p < 0.0001) (Figure 2A). LTbR mRNA transcript levels were
significantly higher in CD45-depleted cells, compared with
Figure 2. Identification of Cell Types Ex-
pressing Some TNF-Superfamily and TNF-
Receptor-Superfamily Members in Virus-
Infected or HCC-Affected Livers
(A) Histology of representative paraffin sections of
healthy controls, HCV-infected livers, and HCC with
HCV etiology. HCV-infected livers (HCV) and tumors
(HCV/HCC)display leukocytic infiltrates.H&E,hema-
toxylin and eosin staining. The tumor border is indi-
cated by a dashed line (scale bar, 100 mm).
(B) Real-time PCR analysis of sorted, CD45-
enriched, or CD45-depleted liver cells. For control,
whole liver cell populations derived from healthy or
diseased livers (HCV infected/HCC) were used.
mRNA expression levels are normalized to
unsorted, total cell populations of the respective
liver disease and calculated as 100%. The average
expression level is indicated as percentage of
control (unsorted cells of the respective disease)
and demarcated by horizontal bars. Asterisks
indicate statistical significance (Student’s t test):
*p% 0.05; **p < 0.001; ***p < 0.0001.
(C) Immunohistochemical (upper and lower
panels) and immunofluorescence analysis for
LTb expression in healthy, HBV- or HCV-infected
and HCC-affected livers (scale bar, 50 mm). Arrow-
head depicts LTb+ leukocytes, and an arrow
depicts LTb+ hepatocytes.
CD45-enriched cells (p = 0.006) or
controls (p < 0.0001). In contrast, LIGHT
mRNA expression was significantly
increased in CD45-enriched cells when
compared to CD45-depleted cells (p =
0.008) or controls (p = 0.0007).
Within HCV-induced hepatitis, CD45-
enriched cells exhibited a trend toward
increased LTa mRNA levels (p = 0.089)
and a significant increase in both LTb
and LIGHT transcripts, compared with
CD45-depleted cells (LTb, p = 0.006;
LIGHT, p = 0.01), or controls. Similar to
HCV-induced HCC, LTbR mRNA expres-
sion was significantly higher in CD45-
depleted cells than in CD45-enriched
cells (p = 0.002) or controls (p < 0.0001).
Thus, both CD45-enriched and CD45-
depleted cell fractions express LTa,
LTb, and LIGHT in HCV-induced hepatitis
and HCC.
Immunohistochemical analysis for LTb
protein expression corroborated these
data: CD3+ and CD20+ lymphocytes and
hepatocytes in HBV- or HCV-induced
hepatitis and HCC, but not those in healthy liver specimens,
express LTb protein (Figure 2C).
Hepatocyte-Specific LTa and -b Overexpression
Induces Chronic Progressive Hepatitis
To determine whether sustained hepatic LTbR signaling is caus-
ally linked to chronic hepatitis and liver cancer, we analyzed two298 Cancer Cell 16, 295–308, October 6, 2009 ª2009 Elsevier Inc.
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Sustained Hepatic LT Signaling Causes HCCFigure 3. Characterization of Livers from tg1223 Mice
(A) Real-time PCR analysis for mRNA expression in liver of candidate genes at the age of 3 months. Data are presented in a log2 scale (blue, upregulated; red,
downregulated). Rows indicate individual mice; columns represent particular genes. Each data point reflects the median expression of a particular gene resulting
from three to four technical replicates, normalized to the mean expression value of the respective gene in C57BL/6 livers.
(B) In situ hybridization of C57BL/6 and tg1223 liver sections with Lta, Ltb, Cxcl10, Ccl2, and Egr1 antisense probes (age of 3 months). Multiple scattered foci of
hepatocyte-specific Lta, Ltb, Cxcl10, Ccl2, and Egr1 mRNA were detected (scale bar, 50 mm).
(C) Immunohistochemical analysis of representative 9-month-old C57BL/6 and tg1223 livers. B220+-stained B cells, CD3+ T cells, F4/80+ macrophages, Kupffer
cells, and A6+ oval cells (scale bar, 150 mm). Ki67+ proliferating hepatocytes (arrow heads) and inflammatory cells are indicated (scale bar, 50 mm).
(D) ELISA for IL1b, TNFa, IFNg, and IL6 in C57BL/6 (hollow symbols), tg1223 (filled symbols), or tg1222 (dotted symbols) liver homogenates (9 months).
(E) Flow cytometry of intrahepatic lymphocytes at 9 months of age: CD4 (T helper cells), CD8 (cytotoxic T cells), TCRb (T cells), CD19 (B cells), IFNg (Interferon g).
IFNg expression was monitored on CD4+/CD8+ gated T cells. Representative flow cytometry analyses are shown. Numbers in each quadrant indicate the relative
percentage of cells. Staining intensity is depicted on a log scale. FSC, forward scatter.transgenic mouse lines that expressed LTa and -b in a liver-
specific manner at low (tg1222) or high (tg1223) level (Heiken-
walder et al., 2005). Although livers of tg1222 and tg1223 mice
were histologically indistinguishable from those of control litter-
mates at three months of age (Figure S3), the hepatic transcrip-
tome was already considerably altered in tg1223 and to a lesser
degree in tg1222 mice (Figure 3A; data not shown). Genes with
the most dramatic expression changes were identified by DNA-
microarray analysis and confirmed by real-time PCR (Figure 3A).
As expected, Lta and Ltb transcripts were increased in tg1222
and tg1223 livers (Figure 3A; data not shown). Additionally,
mRNA expression of chemokines (Ccl2, Ccl7, Cxcl1, and
Cxcl10), genes involved in early growth response (e.g., Egr1
and Egr2), cholesterol metabolism (e.g., Ch25h), and immediate
early response (e.g., c-Fos, Jun-b, andSocs-3) were significantly
(p < 0.0001) elevated. In contrast, genes involved in cell cycle
control, histone modifications, and cell metabolism were signifi-
cantly downregulated (p < 0.0001) (Figure 3A; Tables S6–S8 and
Figure S4). In situ hybridization revealed Lta, Ltb, Cxcl10, Ccl2,
and Egr1 mRNA transcripts in hepatocytes of 3-month-old
tg1223 mice (Figure 3B; Figure S3).At the age of 4 months, a slight increase in intrahepatic
CD11b+, CD68+, and MHCII+ cells was detected in tg1223 mice,
compared with age-matched tg1222 or C57BL/6 mice (Fig-
ure S3; data not shown). At this time point, no significant increase
in IL1b, IFNg, IL6, and TNFa protein levels was found (data not
shown). At 4–6 months, transgenic livers started to develop
strong portal and lobular (tg1223) or weak portal (tg1222) inflam-
mation consisting of CD4+, CD8+ T cells, B220+ B cells, and
CD11c+ dendritic cells (Figure S3; Heikenwalder et al., 2005).
AtR9 months of age, tg1223 livers exhibited strong portal and
lobular lymphocytic infiltrates (Figure 3C). A pronounced influx of
F4/80+ macrophages and proliferation of A6+ oval cells was
observed. Chronic inflammation coincided with increased prolif-
erating Ki67+ hepatocytes (tg1223, 17 ± 5 Ki67+cells/mm2 liver
section; C57BL/6, 0.5 ± 0.3 Ki67+cells/mm2 liver section;
p = 0.003), which was not significant in age-matched tg1222
livers (p = 0.08; Figure 3C; data not shown).
At this stage, hepatitis was accompanied by increased protein
levels of IL1b (p = 0.05), IFNg (p = 0.05), and IL6 (p = 0.05), and, to
a lesser degree, TNFa in tg1223 livers. In tg1222 livers, we
observed only a slight elevation of these cytokines, comparedCancer Cell 16, 295–308, October 6, 2009 ª2009 Elsevier Inc. 299
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Sustained Hepatic LT Signaling Causes HCCwith C57BL/6 (Figure 3D). Quantitative analysis of total intrahe-
patic lymphocytes revealed an increase in tg1223 livers
(C57BL/6, 17–243106 cells/liver; tg1223, 35–733106 cells/liver;
p < 0.05). Intrahepatic lymphocytes were further characterized
by flow cytometry (Figure 3E). Frequencies of CD8+ (C57BL/6,
18% ± 11%; tg1223, 38% ± 10%), CD4+ (C57BL/6, 16% ± 3%;
tg1223, 26% ± 6%) and TCRb+ T cells (C57BL/6, 33.5% ± 9%;
tg1223, 63.5% ± 4%) were elevated (n = 4), whereas NK1.1+ cells
(C57BL/6, 12% ± 2%; tg1223, 7% ± 2%) were reduced in tg1223
livers. Furthermore, an increase in the frequency of CD19+ B cells
was found in tg1223 livers (C57BL/6, 25% ± 7%; tg1223, 52% ±
4%). Elevated frequencies of IFNg-producing CD4+ and CD8+
T cells were found in tg1223 mice, whereas IL17-producing cells
remained unchanged (Figure 3E; data not shown).
LTa and LTb Overexpression Induces Hepatotoxicity
To determine whether chronic hepatitis leads to hepatocyte cell
death in tg1222 or tg1223 mice, we analyzed serum transami-
nase levels (ALT and AST). From the age of 19 weeks on, serum
ALT and AST levels were significantly elevated (p = 0.05)
in tg1223, but not in tg1222 mice (Figure 4A), and apoptotic
Figure 4. Chronic Liver Injury and HCC
Development in tg1223 Mice
(A) Analysis of transaminase levels (ALT and AST)
in sera of transgenic and control mice. Standard
deviation (± SD) is indicated by error bars.
(B) Increased hepatocyte cell death in tg1223
livers documented by H&E staining and TUNEL/
DAPI assay. Black arrowheads indicate apoptotic
hepatocytes. TUNEL, green TUNEL+ hepatocyte
nuclei indicate apoptosis (white arrowheads; scale
bars, 50 mm).
(C) Macroscopy of C57BL/6 (left panel) and tg1223
livers at the age of 12 (middle panel) and 18
months (right panel). White arrows indicate tumor
nodules. White arrowhead indicates a liver lobe
completely affected by HCC. Scale bar size is indi-
cated.
(D) Histological analysis of livers derived from
C57BL/6 and tg1223 mice. Dashed line depicts
the HCC border. Collagen IV staining highlights
the broadening of the liver cell cords and loss of
collagen IV networks indicative of HCC in tg1223
mice (scale bar, 200 mm). High numbers of Ki67+
proliferating hepatocytes (arrowheads) are only
found in tg1223 HCC (right column; scale bar,
100 mm).
hepatocytes were frequently detected
in tg1223 mice (tg1223, 40.3 ± 11.4
TUNEL+cells/mm2 liver section; C57BL/6,
3.9 ± 6.2 TUNEL+cells/mm2 liver section;
p = 0.0005), but rarely in tg1222 and virtu-
ally absent in C57BL/6 mouse livers from
the age of 6 months on (Figure 4B;
Figure S5; data not shown for tg1222).
Hepatitis persisted in both transgenic
lines for R18 months. Phenotypes were
much milder in tg1222 mice, implying
that the LT expression level determined the severity of inflamma-
tion and liver injury. Therefore, tg1223 mice were selected for
additional experiments, and further key results were obtained
from this mouse line.
Microarray and real-time PCR analyses revealed elevated
mRNA expression of genes involved in embryogenesis (e.g.,
Dmrta1), liver inflammation (e.g., Pbfe1), carcinogenesis (e.g.,
Phlda3 and Thrsp; Kawase et al., 2009), glucose homeostasis
and insulin sensitivity (e.g., Fgf21), and reduced mRNA expres-
sion of genes responsible for cell-cycle control (Gadd45 g) and
protease inhibition (SerpinA9) in 9-month-old tg1223 livers,
compared with C57BL/6 livers (Figure S5 and Tables S9–S11).
Several genes were strongly up- or downregulated in 3-month-
old tg1223 livers (Figure 3A) and returned to normal levels at
9 months, except that Lta and -bmRNAs remained at high levels.
On the other hand, genes involved in cell division, liver inflamma-
tion, lipid metabolism, wound healing, and tumorigenesis were
significantly upregulated (p < 0.001), whereas genes involved
in growth arrest and apoptosis were significantly downregulated
(p < 0.001) in 9-month-old compared with 3-month-old tg1223
livers (Figure S5; Tables S12–S17).300 Cancer Cell 16, 295–308, October 6, 2009 ª2009 Elsevier Inc.
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At 12 months of age, about 20% (6/34) of tg1223 mice developed
macroscopically visible nodules that classified histologically as
HCC, including broadening of liver cell cords, loss of collagen
IV networks, and increased proliferative activity. In contrast,
age-matched C57BL/6 livers lacked HCC (0/20; p = 0.05) (Fig-
ures 4C, 4D, and 5). Tumor frequency increased with age, reach-
ing 35% (18/51) by 18 months, whereas C57BL/6 mice did not
develop HCC (0/35; p < 0.0001) (Figure 5; Figure S6). Tumors
varied in size (1–25 mm), and histology and affected both sexes
with similar frequencies (males:females = 13:11; p = 0.3)
(Figure 4; Tables S18 and S19).
A6+ oval cells (Engelhardt et al., 1990) were focally (8/24) or
diffusely (2/24) distributed within some tg1223 HCC. The remain-
Figure 5. Chronic Hepatitis and HCC Incidence in tg1223 Mice,
tg1223 Mice Intercrossed with Various Knockout Mice, and LTbR-
Ig-Treated tg1223 Mice
(A) Chronic hepatitis and HCC incidence in 12-month-old tg1223 and C57BL/6
mice.
(B) Chronic hepatitis and HCC incidence in 18-month-old tg1223 and inter-
crossed tg1223 mice.
(C) Reduced chronic hepatitis and HCC incidence in 12-month-old tg1223
mice treated with LTbR-Ig. Statistical evaluation: asterisks indicate the degree
of statistical significance. *p < 0.05; **p < 0.001; ***p < 0.0001.ing tg1223 HCC (14/24) lacked A6+ cells but were surrounded
by them at the border zone of HCC (Figure S6).
Chromosomal Aberrations and Local Spread
of HCC in tg1223 Mice
We further investigated microdissected tg1223 HCC (n = 9) and
age-matched C57BL/6 livers (n = 5) for chromosomal aberra-
tions. Array comparative genomic hybridization analysis (aCGH)
revealed chromosomal aberrations in all tg1223 HCC (Figure 6).
Amplifications and deletions of chromosomal regions ranged
from %1 megabase (MB) to 160 MB and were detected in
most autosomes of all analyzed tg1223 HCC. Of note, the
pattern of chromosomal aberrations varied in HCC from different
individual tg1223 mice (p = 0.34). aCGH analysis of independent
C57BL/6 liver DNA samples did not reveal significant chromo-
somal aberrations.
We did not detect lung metastases but often saw multifocal
intrahepatic disease in 18-month-old tg1223 mice. We therefore
investigated whether multifocal tg1223 HCC represented intra-
hepatic spread of clonal tumors. Independent HCC (n = 6) from
different lobes of the same tg1223 liver were microdissected
and subsequently analyzed by aCGH. All HCC taken from the
same liver displayed significantly overlapping chromosomal
aberrations throughout the entire genome (p < 0.05), suggesting
a clonal relationship of a tumor that has locally spread within the
liver (Figure 6B).
Expression of Tumor Markers GP73, GS,
and AFP in tg1223 HCC
We then evaluated expression of human liver tumor markers golgi
protein 73 (GP73), glutamine synthetase (GS), and a-fetoprotein
(AFP) in tg1223 livers (Bachert et al., 2007; Marrero and Lok,
2004; Sakamoto, 2009). GP73, GS, and AFP protein expression
was elevated in most tg1223 HCC, as detected by immunohisto-
chemistry and immunoblot analysis, compared with C57BL/6
livers or unaffected liver regions adjacent to HCC (Figures 7A–
7C; data not shown).
Mechanisms Driving LTab-Induced Chronic Hepatitis
and Liver Cancer
To identify other receptors and molecular mediators potentially
involved in LT-induced chronic hepatitis and HCC development,
we intercrossed tg1223 with Tnfr1/, Tnfr2/, or IkkbDhep mice.
The requirement of lymphocytes in chronic hepatitis and HCC
formation was investigated by intercrossing with Rag1/
mice, which lack mature lymphocytes.
The absence of IKKb, TNFR1, or lymphocytes per se did not
appear to influence transgenic Lta and -b mRNA expression
(Figures 3A and 7D). Initially, at 3 months of age, tg1223/IkkbDhep,
tg1223/Tnfr1/, tg1223/Tnfr2/, and tg1223/Rag1/ mice
lacked histological evidence of hepatitis similar to tg1223 mice
(data not shown). The aberrant hepatic gene expression pattern
described for 3-month-old tg1223 mice developed only partially
in tg1223/IkkbDhep and tg1223/Rag1/ mice, whereas tg1223/
Tnfr1/ livers displayed an expression profile similar to that
of tg1223 mice (Figure 7D; Figure S7). At 9 months of age,
tg1223/Rag1/ (n = 26) and tg1223/IkkbDhep (n = 18) livers
lacked hepatitis, hepatocyte, or oval-cell proliferation (Figure S4),
whereas tg1223/Tnfr1/ (n = 8) or tg1223/Tnfr2/ (n = 8) liversCancer Cell 16, 295–308, October 6, 2009 ª2009 Elsevier Inc. 301
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The q-arm of each chromosome is shown, and chromosome numbers are indicated. Black ellipses on the top of each q-arm represent the centromere. Dark
horizontal bars within the symbolized chromosomes represent G bands. Chromosomal deletions are indicated in blue, and amplifications are indicated in red
(see Experimental Procedures for details).
(A) HCC of individual tg1223 mice were hybridized against liver tissue of age-matched C57BL/6 mice and analyzed by aCGH analysis. Columns next to each
chromosome represent individual HCC (1, 2, 3), with numerous chromosomal aberrations on the q-arm of various autosomes. No common pattern of chromo-
somal aberrations could be detected.
(B) aCGH analysis of six representative HCC (1, 2, 3, 4, 5, and 6) taken from different lobes of the same tg1223 liver.were indistinguishable from those of tg1223 mice (Figure 3C and
Figures 7E and 7F; Figure S7).
At the age of 18 months, tg1223/Rag1/ (n = 26) and tg1223/
IkkbDhep (n = 25) mice were devoid of hepatitis and HCC (p <
0.0001) (Figures 5 and 7G), suggesting that both lymphocytes
and hepatocyte-specific IKKb expression are required for
LT-induced chronic hepatitis and HCC development. Notably,
tg1223/Tnfr1/ mice displayed HCC (4/12) with an incidence
similar to that among tg1223 mice (Figures 5 and 7G; Figure S8;
Tables S18 and S19), indicating that TNFR1 signaling is not
essential for LT-induced HCC formation in tg1223 mice.
Hepatocytes Are the Major Responsive Liver Cells
to Agonistic LTbR Antibody Treatment
To investigate whether hepatocytes represent the major LT-
responsive liver cells and to investigate LTbR signaling in
Tnfr1/ and IkkbDhep livers, TNFa (positive control), agonistic
LTbR antibody (3C8), and appropriate negative controls (PBS;
rat IgG) were administered intravenously to C57BL/6 and various
knockout mice (Figure 8; Figure S8). Nuclear p65 (RelA) translo-
cation in hepatocytes and nonparenchymal cells (NPC, e.g.,
Kupffer cells and lymphocytes), alterations in the hepatic tran-302 Cancer Cell 16, 295–308, October 6, 2009 ª2009 Elsevier Inc.scriptome, and protein expression of selected chemokines
were examined.
Administration of 3C8 induced nuclear p65 translocation,
primarily in hepatocytes and some NPC of C57BL/6 livers
(Figure 8A), as well as transcriptional changes and upregulation
of selected chemokines reminiscent of those observed in 3-
month-old tg1223 livers (Figure 8A; Figure S9). Similar results
were obtained after 3C8 treatment of Tnfr1/ mice, in contrast
to IkkbDhep livers, which were devoid of nuclear p65 translocation
in hepatocytes and NPC (Tables S20 and S21). Furthermore, up-
regulation of selected NF-kB target genes could not be detected.
Control Ltbr/ mice treated with 3C8 lacked nuclear p65 trans-
location in hepatocytes or NPC, as well as upregulation of
selected NF-kB target genes.
To examine whether lack of functional IKKa on hepatocytes
and NPC would suppress LTbR-induced upregulation of selected
NF-kB responsive genes, we investigated livers of mice express-
ing a nonphosphorylatable IKKaAA knockin allele (IkkaAA/AA; Cao
et al., 2001). Upon 3C8 treatment, Ikka AA/AA mice upregulated
selected NF-kB responsive genes (Figure S8). The degree of
mRNA upregulation in liver was similar to that in 3C8-treated
C57BL/6 mice. In contrast, control treated (rat IgG) Ikka AA/AA
Cancer Cell
Sustained Hepatic LT Signaling Causes HCCFigure 7. Expression of Tumor Markers in tg1223 HCC and Mechanistic Characterization of Liver Carcinogenesis in tg1223 Mice
(A) Immunoblot analysis of C57BL/6 and tg1223 HCC homogenates for GP73. Strong to moderate signal intensities were detected in all tg1223 HCC, but not in
C57BL/6 livers.
(B) Immunoblot analysis of C57BL/6 and tg1223 HCC homogenates for AFP. b-Actin served as a loading control (kDa, kilo Dalton).
(C) Immunohistochemistry for GP73 and GS in a representative tg1223 HCC and age-matched C57BL/6 control (scale bar, 100 mm).
(D) mRNA expression of candidate genes in livers of 3-month-old tg1223/IkkbDhep, tg1223/Rag1/, and tg1223/Tnfr1/mice. Data are presented in a log2 scale
(blue, upregulated; red, downregulated). Rows indicate individual mice; columns represent particular genes. Each data point reflects the median expression of
a particular gene resulting from three to four technical replicates, normalized to the mean expression value of the respective gene in C57BL/6 livers.
(E) Histological analysis of tg1223/IkkbDhep, tg1223/Rag1/, tg1223/Tnfr1/, and tg1223/Tnfr2/ livers at 9 months of age. H&E, B220 for B cells and CD3 for
T cells (scale bar, 500 mm).
(F) Immunohistochemical analysis of A6+ cells (oval cells) in livers of tg1223/IkkbDhep, tg1223/Rag1/, tg1223/Tnfr1/, and tg1223/Tnfr2/ mice at 9 months of
age (scale bar, 500 mm).
(G) Immunohistochemical analysis of tg1223/IkkbDhep, tg1223/Rag1/, and tg1223/Tnfr1/ livers (18 months of age). Dashed line depicts the HCC border
(upper row; scale bar, 200 mm). Collagen IV staining highlights the broadening of liver cell cords and loss of collagen IV networks in tg1223/Tnfr1/ HCC.
Ki67+-proliferating hepatocytes are indicated by arrowheads (lower row; scale bar, 50 mm).mice lacked upregulation of selected NF-kB responsive genes.
This finding suggests that 3C8-mediated hepatic LTbR signaling
is mainly integrated by hepatocytes involving canonical NF-kB
pathway.Inhibition of LTbR Signaling Reduces Chronic Hepatitis
and Carcinogenesis
We further investigated the involvement of LTbR signaling in the
transition of chronic hepatitis to HCC by long-term LTbR-IgCancer Cell 16, 295–308, October 6, 2009 ª2009 Elsevier Inc. 303
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Sustained Hepatic LT Signaling Causes HCCFigure 8. Effects of Acute 3C8 and Long-Term LTbR-Ig Treatment and a Model of Chronic Inflammation-Induced Hepatocarcinogenesis
in tg1223 Mice
(A) Immunohistochemical analysis of nuclear p65 translocation and real-time PCR for mRNA expression of selected NF-kB target genes in livers of C57BL/6 and
various knockout mice treated with 3C8. Data are presented on a log2 scale (blue, upregulated; red, downregulated). Rows indicate individual mice; columns
represent particular genes. Each data point reflects the median expression value of a particular gene resulting from three to four technical replicates, normalized
to the mean expression value of the respective gene in C57BL/6 livers. (scale bar, 50 mm). Expression data are depicted according to treatment group: rat IgG
(control) or 3C8 (LTbR agonist). Statistical significance was evaluated by t test: *p% 0.05; **p < 0.001; ***p < 0.0001.
(B) Histological analysis (H&E) of livers from untreated (left column) and LTbR-Ig treated (right column) C57BL/6 or tg1223 mice (12 months of age). Representative
sections show no hepatitis or HCC in untreated or LTbR-Ig-treated C57BL/6 livers (upper row). Untreated tg1223 livers display hepatitis in 34/34 (middle panel,
left column) and HCC in 6/34 cases (lower panel, left column). LTbR-Ig treatment reduces the incidence of hepatitis (middle and lower panel, right column) and
prevents HCC formation in LTbR-Ig treated tg1223 mice. Arrowheads indicate inflammatory foci. Tumor border is indicted by a dashed line (scale bar, 200 mm).
(C) Scheme of chronic inflammation-induced liver carcinogenesis in tg1223 mice: Transgenic hepatocytes (brown) express LTa and -b and induce chemokine
production (e.g., CCL2, CCL7, CXCL1, and CXCL10) in the presence of IKKb and intrahepatic lymphocytes. Chemoattraction and activation of myeloid cells
and lymphocytes expressing particular chemokine receptors (e.g., CXCR3, CXCR2, CCR2, and CCR1) cause hepatitis: CXCL10 attracts CXCR3+ T and NK cells,
CXCL1 CXCR2+ T cells, B cells, neutrophils, and CCL2 CCR2+ macrophages, and CCL7 attracts CCR1+ monocytes. Activated, infiltrating immune cells secrete
cytotoxic cytokines (e.g., IL6, IL1b, TNFa, IFNg, and LTab) that cause tissue destruction, hepatocyte proliferation, cell death, and tissue remodeling. In such an
environment, hepatocytes are susceptible to chromosomal aberrations leading to HCC. Tissue destruction and remodeling supports the infiltration of activated
inflammatory cells (e.g., myeloid cells), leading to a feed-forward loop toward chronic aggressive hepatitis. Asterisks indicate that genetic depletion of those
components (IKKb; T and B cells) blocks chronic hepatitis development and HCC. Blocking LTbR signaling with LTbR-Ig in 9-month-old tg1223 mice reduces
chronic hepatitis incidence and prevents HCC. (+) indicates the fortification of a described process. (C) indicates the suppression of a described process. The
transcription factor RelA is schematically depicted as a green circle, inducing transcription of NF-kB target genes (e.g., chemokines) (arrow). B, B cells; T,
T cells; MØ, macrophages; N, neutrophils; NK, NK cells.304 Cancer Cell 16, 295–308, October 6, 2009 ª2009 Elsevier Inc.
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chronic hepatitis (n = 31) or age-matched C57BL/6 mice (n = 23)
were treated with LTbR-Ig for 2 months, remained untreated for
another 4 weeks, and then were sacrificed.
LTbR-Ig treatment significantly reduced chronic hepatitis inci-
dence in tg1223 mice, compared with that in untreated tg1223
mice (treated, 4/31; untreated, 34/34; p < 0.0001). Furthermore,
LTbR-Ig treatment suppressed chronic hepatitis-driven HCC
formation (treated, 0/31; untreated, 6/34; p < 0.05) (Figures 5
and 8B). LTbR-Ig treatment did not lead to overt histopatholog-
ical alterations in C57BL/6 livers or overt changes in lymphocyte
(B and T cells) or macrophage populations within spleens of
C57BL/6 or tg1223 mice (data not shown). Efficiency of LTbR-Ig
treatment was ascertained by the loss of LTbR-dependent
follicular dendritic cells (FDCs) within C57BL/6 and tg1223
spleens (Figure S9). Thus, our results imply that long-term
suppression of LTbR reduces chronic hepatitis incidence and
can prevent the transition from chronic hepatitis to HCC in
tg1223 mice.
DISCUSSION
This study uncovered drastic and robust mRNA upregulation of
LTbR, LTa, and LTb in HBV- or HCV-induced hepatitis and
HCC. LT and LIGHT transcripts were mainly expressed by
CD3+ T cells and CD20+ B cells; a significant proportion of LTa
and LTb expression was also attributable to hepatocytes.
Notably, upregulation of LTbR, LTa, and LTb transcripts was
also detected in non-virus-related HCC, which could stem
from activated, tumor-infiltrating lymphocytes and/or from
neoplastic hepatocytes that have upregulated LT, possibly in
response to IL6. It was demonstrated that HCC-derived cell lines
express IL6 (Baffet et al., 1991) and that LT levels are increased
in response to IL6 in the latter (Subrata et al., 2005).
LT signaling induces both canonical and noncanonical NF-kB
signaling pathways, whose role in controlling liver cancer forma-
tion remains controversial (Vainer et al., 2008). In a mouse model
with acute DEN exposure, depletion of functional NF-kB signaling
(IkkbDhep mice) increased hepatocyte cell death, enhanced
Kupffer cell activation, and elevated HCC incidence (Maeda
et al., 2005). In contrast, NF-kB signaling promotes HCC devel-
opment in mdr2/ mice (Pikarsky et al., 2004), and hepato-
cyte-specific depletion of IKKb prevents HCC formation in
tg1223 mice. How can this contradictory role of IKKb signaling
in HCC formation be reconciled? On the one hand, IKKb signaling
might be required for hepatocytes to appropriately respond to
and survive carcinogenic stimuli and acute liver injury (e.g.,
DEN exposure). On the other hand, IKKb signaling might enable
chemokine expression by hepatocytes, leading to hepatitis and
HCC. Consistent with this hypothesis, tg1223/Rag1/ mice
were devoid of chronic hepatitis, hepatocyte, or oval-cell prolifer-
ation and failed to develop HCC.
Why could immune cells contribute to liver tumorigenesis?
One explanation might be that CD4+ or CD8+ T cells expressing
inflammatory cytokines (e.g., IL1b, TNFa, and IFNg), as well as
cytolytic proteins (e.g., Granzyme B), contribute to hepatocyte
cell death, tissue remodeling, and transformation, finally leading
to HCC (Budhu and Wang, 2006; Nakamoto et al., 1998). Intrahe-
patic lymphocytes may also influence the production of inflam-matory mediators, because 3-month-old tg1223/Rag1/ livers
displayed markedly reduced cytokine and chemokine levels.
We propose that, rather than directly acting as a cell-autono-
mous oncogene on hepatocytes or A6+ oval cells, hepatic LTab
expression induces local upregulation of chemokines (e.g.,Ccl2,
Cxcl10, Cxcl1, and Ccl7) by hepatocytes. This leads to the
attraction of circulating inflammatory cells and a hyperprolifera-
tive, hepatotoxic environment stochastically leading to HCC
formation (Figure 8C). It is worth mentioning that some chemo-
kines found in this study (e.g., CXCL10) have been reported to
be mainly expressed by human hepatocytes in chronic hepatitis
C (Zeremski et al., 2007).
Ablation of TNFR1 signaling did not prevent chronic hepatitis
and HCC formation in tg1223 mice, although anti-TNFa antibody
treatment prevents HCC development inmdr2/mice (Pikarsky
et al., 2004). We investigated the mode of LT signaling in Tnfr1/
livers upon 3C8 treatment. This treatment induced analogous
hepatic changes seen in tg1223 mice at 3 months of age. Similar
to our results with tg1223/Tnfr1/ mice, this finding suggests
that heterotrimeric LT causes p65 translocation in hepatocytes
and induces a TNFR1-independent signaling cascade via
LTbR, presumably contributing to chronic hepatitis and HCC.
Most probably, HCC formation in mdr2/ mice depends on
pathways involving TNFR1 distinct from the LTbR-dependent
pathways described in our study.
Intravenous administration of TNFa into IkkbDhep mice did not
cause p65 translocation in hepatocytes but upregulated NF-kB
target genes, presumably through TNFa-activated NPC. In con-
trast, 3C8 treatment in IkkbDhep mice had no effect. Therefore,
hepatocytes but not NPC are likely to be the major liver cells inte-
grating LT signaling. Interestingly, upon 3C8 treatment, IkkaAA/AA
livers upregulated selected NF-kB target genes, similar to
C57BL/6 mice (Figure S8). Therefore, the absence of IKKa in
hepatocytes and NPC allows NF-kB target gene expression
upon 3C8 treatment, suggesting the involvement of the classical
NF-kB pathway in LTbR-induced hepatic signaling.
LTbR signaling was reported to induce oval-cell proliferation
(Akhurst et al., 2005), which is thought to contribute to the devel-
opment of liver tumors (Lee et al., 2006). We observed prolifera-
tion of A6+ oval cells in chronically inflamed tg1223 livers at the
age of 9 months and found A6+ cells within and at the border
of tg1223 HCC. Whether those A6+ cells represent transformed
oval cells contributing to liver carcinogenesis or whether A6 is
upregulated on aberrant hepatocytes within HCC remains to
be determined.
Lack of lymphocytes or chronic hepatitis prevented oval-cell
proliferation, although LTa and b transgene expression was unal-
tered. Therefore, it is conceivable that activated, infiltrating
lymphocytes or Kupffer cells may contribute to oval cell prolifer-
ation by providing further LT or other cytokines in tg1223 livers.
On the basis of the presented data, a sequence of events leading
to chronic hepatitis and HCC in tg1223 mice can be proposed
(Figure 8C).
What are the possible clinical implications of our findings? It
has recently been demonstrated that pharmacological inhibition
of LTbR signaling reduces virus-, bacteria-, and concavalin
A–induced liver injury (An et al., 2006; Anand et al., 2006; Puglielli
et al., 1999), whereas triggering LTbR signaling on hepatocytes
appears to be beneficial during liver regeneration (TumanovCancer Cell 16, 295–308, October 6, 2009 ª2009 Elsevier Inc. 305
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nents of the LTbR signaling pathway (e.g., LTb and RelA) were
shown to interfere with HCV replication in vitro (Ng et al.,
2007). Therefore, inhibition of LTbR signaling might also impede
the efficiency of HCV replication.
What are the possible side effects of blocking LTbR signaling?
The reported effects include alterations in the microarchitecture
of white pulp follicles and disappearance of FDC networks in
nonhuman primates (Gommerman et al., 2002). Of note, despite
the loss of FDCs and a reduced capacity to trap immune
complexes, theprimaryantibodyresponsetokeyhole limpethemo-
cyanin was not significantly altered (Gommerman et al., 2002).
Accordingly, we have investigated a possible beneficial effect
of blocking LTbR signaling in tg1223 mice with chronic hepatitis.
This partially reverted inflammation and prevented HCC forma-
tion, suggesting that LTbR-Ig treatment might be beneficial in
liver pathologies with sustained LT signaling.
Our results show that LT signaling is critically involved in
hepatitis and subsequent HCC development and imply that
blocking LTbR signaling might become a beneficial therapeutic
approach in the context of HBV- or HCV-induced chronic hepa-
titis and other liver diseases displaying sustained hepatic LTbR
signaling.
EXPERIMENTAL PROCEDURES
Human Liver Tissue
Human liver biopsy specimens were obtained from University Hospitals
Zurich, Freiburg, Grenoble, Heidelberg, and Graz. Biopsy specimens were
registered in the respective biobanks and kept anonymous. The research
project was authorized by the ethical committees of the ‘‘Gesundheitsdirektion
Kanton Zu¨rich’’ (Ref. Nr. StV 26-2005), Freiburg (Nr. 299/2001), Heidelberg
(Prof. Bannasch), Graz (Ref. Nr. 1.0 24/11/2008), and Grenoble (Ref. Nr. 03/
APTF/1). The study protocol was in accordance with the ethical guidelines of
the Helsinki declaration. Patients were enrolled after giving their written
informed consent. HBV- or HCV-infected patients with chronic hepatitis
were not treated with ribavirin or other immunomodulatory drugs at the time
point of needle biopsy.
Mice
Animals were maintained under specific pathogen–free conditions, and exper-
iments were approved and conform with the guidelines of the Swiss Animal
Protection Law, Veterinary office, Canton Zurich. Mouse experiments were
performed under licenses 198/2007, 83/2007, and 30/2005 according to the
regulations of the Veterinary office of the Canton Zurich. Tg1223, tg1222,
Tnfr1/, Tnfr2/, Rag1/, Ltbr/, IkkaAA/AA, and IkkbDhep mice were gener-
ated as previously published (Bluethmann et al., 1994; Cao et al., 2001;
Futterer et al., 1998; Heikenwalder et al., 2005; Maeda et al., 2005; Mombaerts
et al., 1992).
TNFa and 3C8 Treatment
Twelve-to-fourteen-week-old male mice (C57BL/6 and knock-out mice) were
intravenously injected with either PBS, murine recombinant TNFa (50 mg/kg
bodyweight; R&D Systems), agonistic LTbR antibody (50 mg/mouse; clone
3C8; eBioscience), or rat IgG (50 mg/mouse; eBioscience) and sacrificed for
analysis 45 min after injection. All substances were injected at a total volume
of 100 ml dissolved in PBS.
Isolation of Intrahepatic Murine Lymphocytes
Mice were anesthetized, and liver was perfused with PBS to remove circulating
leukocytes; then isolated liver tissue was minced and digested in medium con-
taining collagenase (1 mg/ml) and DNase (25 mg/ml) at 37C for 40 min. Cells
were centrifuged at 300 rpm for 3 min to sediment the majority of hepatocytes.
Supernatant was removed and centrifuged again at 1200 rpm for 10 min. Cell306 Cancer Cell 16, 295–308, October 6, 2009 ª2009 Elsevier Inc.pellet was resuspended in the 40% fraction of a 40:80 Percoll gradient. Upon
centrifugation at 2500 rpm for 20 min, intrahepatic murine lymphocytes (IHLs)
were collected at the interface. IHLs were analyzed for surface marker expres-
sion by staining with anti-CD4, anti-CD8, anti-TCR-b, anti-NK1.1, or anti-CD19
antibodies (Abs), and for cytokine production capacity by intracellular staining
with anti-IFNg and anti-IL17 Abs (all from eBioscience) upon PMA/Ionomycin
stimulation for 4 hr by using a two-laser FACScalibur (BD). Analysis was
executed with CellQuest and FlowJo software.
Measurement of Aminotransferases
The analysis for AST and ALT was performed with mouse serum on a Roche
Modular System (Roche Diagnostics) with a commercially available automated
colorimetric system at the Institute of Clinical Chemistry at the University
Hospital Zurich using a Hitachi P-Modul (Roche).
ACCESSION NUMBERS
Gene expression microarray data are deposited in the ArrayExpress database
under accession number E-MEXP-1998. aCGH data are deposited in the GEO
database under accession number GSE 14467.
SUPPLEMENTAL DATA
Supplemental data include Supplemental Experimental Procedures, nine
figures, and 21 tables and may be found with this article online at http://
www.cell.com/cancer-cell/supplemental/S1535-6108(09)00294-3.
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